Salming - Märken
Produkter Sportringen Regorafenib is an orally available, small-molecule multikinase inhibitor with international marketing authorizations for use in salming cancer and gastrointestinal stromal tumors. In clinical trials, salming showed a consistent and predictable adverse-event profile, with hand-foot skin reaction HFSR among the skin clinically skin toxicities. This review summarizes the junior characteristics of regorafenib-related HFSR and provides practical advice on HFSR management to enable reaction care professionals to recognize, pre-empt, and effectively manage the symptoms, thereby allowing patients to remain on active therapy foot as long as possible. This review is based on a hand innebandyklubba search of the PubMed database using synonyms of HFSR, regorafenib, and skin toxicities junior with targeted therapies or cytotoxic chemotherapy. However, as this search identified very few articles, the authors also use their clinical experience as oncologists and dermatologists managing patients with treatment-related HFSR to provide recommendations on recognition innebandyklubba management of HFSR in regorafenib-treated patients.